
Prostate‐specific membrane antigen (PSMA)‐targeted radionuclide therapy (TRT) has demonstrated efficacy and tolerability with a dose–response effect in phase I/II trials in men with metastatic castration‐resistant prostate cancer (mCRPC).
Like
Save
Share